# DPMAS in the Management of Severe Acute Liver Injury

**Authors:** Maiko Alejandro Tavera Díaz, Annia Aguilar Loayza, Carolina Beatriz Mejía Vargas, Juan Fernando Mamani Ochoa

PMC · DOI: 10.1155/crhe/6456187 · Case Reports in Hepatology · 2026-01-13

## TL;DR

A 67-year-old man with severe liver injury caused by CMV was successfully treated with antiviral therapy and DPMAS, avoiding the need for a liver transplant.

## Contribution

Demonstrates the effectiveness of DPMAS and antiviral therapy in treating CMV-induced acute liver injury in an immunocompetent patient.

## Key findings

- The patient showed clinical and biochemical improvement after 5 DPMAS sessions and 4 weeks of antiviral therapy.
- Liver biopsy confirmed CMV-related hepatitis with signs of hepatocyte regeneration.
- The treatment avoided the need for liver transplantation.

## Abstract

Acute liver injury is a severe disease in which a hepatic and later systemic inflammatory response is triggered, generally induced by paracetamol intoxication, undetermined causes, drugs, and hepatotropic and nonhepatotropic viruses.

A 67‐year‐old immunocompetent male with severe acute liver injury secondary to Cytomegalovirus (CMV) infection presented with a 2‐week history of anorexia, asthenia, adynamia, generalized weakness, myalgia, and jaundice. Laboratory tests revealed hyperbilirubinemia, hypertransaminasemia, coagulopathy, and acute kidney injury, and tests for hepatitis A, B, C, HIV, and autoimmune hepatitis were negative, while PCR was positive for CMV. Patient was treated with N‐acetylcysteine, albumin, valganciclovir, and liver support therapy using the dual plasma molecular adsorption system (DPMAS). Fundus examination showed CMV retinitis, and liver biopsy confirmed acute hepatitis with CMV cytopathic changes and areas of hepatocyte regeneration. After 5 sessions of DPMAS and 4 weeks of antiviral therapy, he showed clinical and biochemical improvement with native liver recovery and was discharged with outpatient follow‐up.

This case highlights the successful early recognition and prompt initiation of appropriate treatment using antiviral therapy and liver support therapy in managing severe CMV‐induced acute liver injury in an immunocompetent patient, potentially averting the need for liver transplantation.

## Linked entities

- **Chemicals:** N-acetylcysteine (PubChem CID 12035), valganciclovir (PubChem CID 135413535)
- **Diseases:** CMV infection (MONDO:0005132), acute hepatitis (MONDO:0002251), coagulopathy (MONDO:0001531), acute kidney injury (MONDO:0002492)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12800567/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12800567/full.md

## References

10 references — full list in the complete paper: https://tomesphere.com/paper/PMC12800567/full.md

---
Source: https://tomesphere.com/paper/PMC12800567